<table>
<thead>
<tr>
<th><strong>Title</strong></th>
<th>Enhancing chemotherapy efficacy in pten-deficient prostate tumors by activating the senescence-associated antitumor immunity</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Author(s)</strong></td>
<td>Toso, A; Revandkar, A; Di Mitri, D; Guccini, I; Proietti, M; Sarti, M; Pinton, S; Zhang, J; Kalathur, M; Civenni, G; Jarrossay, D; Montani, E; Marini, C; Garcia-Escudero, R; Scanziani, E; Grassi, F; Pandolfi, PP; Catapano, CV; Alimonti, A</td>
</tr>
<tr>
<td><strong>Citation</strong></td>
<td>Cell Reports, 2014, v. 9 n. 1, p. 75-89</td>
</tr>
<tr>
<td><strong>Issued Date</strong></td>
<td>2014</td>
</tr>
<tr>
<td><strong>URL</strong></td>
<td><a href="http://hdl.handle.net/10722/219920">http://hdl.handle.net/10722/219920</a></td>
</tr>
<tr>
<td><strong>Rights</strong></td>
<td>This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.</td>
</tr>
</tbody>
</table>
Enhancing Chemotherapy Efficacy in \textit{Pten}-Deficient Prostate Tumors by Activating the Senescence-Associated Antitumor Immunity

**Graphical Abstract**

**Highlights**
- \textit{Pten}-loss-induced cellular senescence is characterized by an immunosuppressive SASP
- SASP reprogramming restores senescence surveillance and tumor clearance
- Senescent secretome reprogramming enhances chemotherapy efficacy
- The senescent secretome depends on the genetic background of senescent tumor cells

**Authors**
Alberto Toso, Ajinkya Revandkar, ..., Carlo V. Catapano, Andrea Alimonti

**Correspondence**
andrea.alimonti@ior.iosi.ch

**In Brief**
Cytokines released by senescent cells can have pro- as well as antitumorigenic effects. Here, Toso et al. show that cytokines released by \textit{Pten}-null senescent prostate tumors drive an immunosuppressive tumor microenvironment. Pharmacological inhibition of the Jak2/Stat3 pathway in \textit{Pten}-deficient prostate tumors reprograms the senescence-associated cytokine network, leading to an antitumor immune response that enhances chemotherapy efficacy. These data demonstrate that immune surveillance of senescent tumor cells can be suppressed in specific genetic backgrounds but is also evoked by pharmacological treatments.

Toso et al., 2014, Cell Reports 9, 75–89

October 9, 2014 ©2014 The Authors
http://dx.doi.org/10.1016/j.celrep.2014.08.044
Enhancing Chemotherapy Efficacy in \textit{Pten}-Deficient Prostate Tumors by Activating the Senescence-Associated Antitumor Immunity

Alberto Toso,1 Ajinkya Revandkar,1,8 Diletta Di Mitri,1 Ilaria Guccini,1 Michele Proietti,2 Manuela Sarti,1 Sandra Pinton,1 Jiangwen Zhang,2 Madhuri Kalathur,1,6 Gianluca Civenni,1 David Jarrossay,2 Erica Montani,1 Camilla Marini,2 Ramon García-Escudero,1,6,9 Eugenio Scanziani,4,5 Fabio Grassi,2 Pier Paolo Pandolfi,7 Carlo V. Catapano,1 and Andrea Alimonti1,8,*

1Institute of Oncology Research (IOR) and Oncology Institute of Southern Switzerland (IOSI), Bellinzona 6500, Switzerland
2Institute for Research in Biomedicine (IRB), Bellinzona 6500, Switzerland
3Faculty of Arts and Sciences (FAS), Center for Systems Biology, Harvard University, Cambridge, MA 02138, USA
4Department of Animal Pathology, University of Milan, Milan 20139, Italy
5Mouse and Animal Pathology Laboratory, Fondazione Filarete, Milan 20139, Italy
6Molecular Oncology Unit, CIELMAT, Madrid 28040, Spain
7Cancer Genetics Program, Beth Israel Deaconess Cancer Center, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
8Faculty of Biology and Medicine, University of Lausanne, UNIL, Rue du Bugnon 21, Lausanne 1011, Switzerland
9Oncogenomics Unit, Institute of Biomedical Research, Hospital “12 de Octubre”, 28041 Madrid, Spain
*Correspondence: andrea.alimonti@ior.iosi.ch
http://dx.doi.org/10.1016/j.celrep.2014.08.044
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).

SUMMARY

Prosenescence therapy has recently emerged as a novel therapeutic approach for treating cancer. However, this concept is challenged by conflicting evidence showing that the senescence-associated secretory phenotype (SASP) of senescent tumor cells can have pro- as well as antitumorigenic effects. Herein, we report that, in \textit{Pten}-null senescent tumors, activation of the Jak2/Stat3 pathway establishes an immunosuppressive tumor microenvironment that contributes to tumor growth and chemoresistance. Activation of the Jak2/Stat3 pathway in \textit{Pten}-null tumors is sustained by the downregulation of the protein tyrosine phosphatase PTPN11/SHP2, providing evidence for the existence of a novel PTEN/SHP2 axis. Importantly, treatment with docetaxel in combination with a JAK2 inhibitor reprograms the SASP and improves the efficacy of docetaxel-induced senescence by triggering a strong antitumor immune response in \textit{Pten}-null tumors. Altogether, these data demonstrate that immune surveillance of senescent tumor cells can be suppressed in specific genetic backgrounds but also evoked by pharmacological treatments.

INTRODUCTION

Cellular senescence, an irreversible cell growth arrest involving the p53 and the p16INK4A tumor suppressors, can be triggered by different insults including activation of oncogenes (oncogene-induced senescence [OIS]) or loss of tumor-suppressor genes (Braig et al., 2005; Chen et al., 2005; Collado, 2010). Over the past years, several in vivo evidences have demonstrated that senescence opposes tumor initiation and progression in different mouse models (Collado, 2010; Nardella et al., 2011). However, recent findings demonstrate that senescent tumor cells secrete a variety of immune modulators and inflammatory cytokines, referred to as the senescence-associated secretory phenotype (SASP), that mediate opposing and contradictory effects. The SASP can stimulate the innate and adaptive antitumor immune response (a process designated as “senescence surveillance”), leading to tumor clearance, but also promotes tumorigenesis by supporting the proliferation of neighboring tumor cells (Kang et al., 2011; Xue et al., 2007; Coppe et al., 2010; Rodier and Campisi, 2011; Davalos et al., 2010). Of note, the SASP can also hinder chemotherapy efficacy (Jackson et al., 2012). Therefore, the contradictory effects of the SASP cast doubts over the possibility to use treatments that enhance senescence for cancer therapy (Collado, 2010; Nardella et al., 2011). Moreover, whereas cytokines released by senescent tumors have been shown to positively regulate the antitumor immune response in some experimental models, it is unknown whether cytokines released by senescent tumors may also favor an immunosuppressive tumor microenvironment. An intriguing possibility is that the genetic background of senescent tumor cells may dictate the strength and composition of the cytokines released by the tumor, therefore impacting differently on the tumor microenvironment, specifically the immune system. We have previously demonstrated that \textit{Pten}-loss-induced cellular senescence (PICS) is a novel type of cellular senescence response that occurs in vivo and that can be enhanced by pharmacological treatments (Alimonti et al., 2010). \textit{Pten}-null prostate
conditional mice (Pten\textsuperscript{pc−/−}) develop a prostatic intraepithelial neoplasia (PIN) characterized by a strong senescence response that progresses to invasive adenocarcinoma. This suggests that the SASP of Pten\textsuperscript{pc−/−} tumors may drive protumorigenic rather than antitumorigenic effects. Thus, the concomitant presence of a senescent component and a proliferative compartment within the same tumor, along with a previously uncharacterized SASP and tumor immune response, makes Pten\textsuperscript{pc−/−} mice a suitable mouse model to study the composition of the SASP and develop treatments that reprogram the protumorigenic effects of the senescent secretome.

**RESULTS**

**Pten-Null Senescent Tumors Are Characterized by an Immunosuppressive Tumor Microenvironment**

Starting from 7 weeks of age, Pten\textsuperscript{pc−/−} mice develop PIN, a pre-malignant prostatic lesion characterized by a strong senescence response, as indicated by the senescence-associated β-galactosidase (SA-β-gal) positivity; fluorescein di-β-D-galactopyranoside staining; and increased expression of p16, p21, and plasminogen activator inhibitor-1 (Figures 1A, left, and S1A; Collado and Serrano, 2006). To characterize the cytokine profile of Pten\textsuperscript{pc−/−} senescent tumors, we used magnetic-activated cell sorting (MACS) to isolate and separate prostate epithelial cells from both stromal and immune cells (Figure 1A, right). The efficiency of purification was controlled by fluorescence-activated cell sorting (FACS) analysis (Figure S1B). Purified Pten\textsuperscript{pc−/−} epithelial cells were lysed and protein extracts loaded in a cytokine protein array to allow high-throughput multianalyte profiling of 40 different cytokines. Interestingly, the SASP of PICS was characterized by increased levels of several cytokines reported to play a negative role in cancer by favoring an immunosuppressive tumor microenvironment (Vanneman and Dranoff, 2012; Acharyya et al., 2012; Ostrand-Rosenberg and Sinha, 2009; Figures 1B, left, and S1C). However, potent chemotactant cytokines that have been previously shown to play a role in the process of inflammation associated to senescence surveillance in OIS (Xue et al., 2007) were also upregulated in Pten\textsuperscript{pc−/−} senescent tumors (Figures 1B, right, and S1C). In line with the cytokine array profile, FACS analysis showed that Pten\textsuperscript{pc−/−} tumors were strongly infiltrated by CD11b\textsuperscript{+}Gr-1\textsuperscript{+} myeloid cells, in absence of CD4\textsuperscript{+}, CD8\textsuperscript{+}, and natural killer (NK) infiltrates (Figures 1C and S1D). CD11b\textsuperscript{+}Gr-1\textsuperscript{+} myeloid cells were granulocytic myeloid-derived suppressor cells (MDSCs) (Figure S1E), an immune-suppressive subset that blocks both proliferation and activity of CD4\textsuperscript{+}, CD8\textsuperscript{+}, and NK cells (Gabrilovich and Nagaraj, 2009). To assess the suppressive activity of CD11b\textsuperscript{+}Gr-1\textsuperscript{+} cells in vivo, we sorted these cells directly from the Pten\textsuperscript{pc−/−} tumors and cocultured them with CD8\textsuperscript{+} T cells. Notably, tumor-infiltrating CD11b\textsuperscript{+}Gr-1\textsuperscript{+} cells suppressed the proliferation of CD8\textsuperscript{+} T cells (Figure 1D). Presence of MDSCs explained why CD8\textsuperscript{+} T and NK cells recovered from Pten\textsuperscript{pc−/−} tumors were not cytotoxic (Figure S1F and S1G).

Recent evidence in a different mouse model indicates that senescent tumor cells are cleared by the immune system, a process termed senescence surveillance. Impairment of this response results in the development of aggressive tumors because the remaining senescent cells support tumorigenesis by secreting a variety of cytokines that favor the growth of non-senescent tumor cells (Xue et al., 2007; Kang et al., 2011). We then speculated that the immunosuppressive tumor microenvironment of Pten\textsuperscript{pc−/−} tumors could impair senescence surveillance sustaining tumor progression. We therefore monitored the number of senescent cells in Pten\textsuperscript{pc−/−} tumors at different times (from 7 to 15 weeks of age; Trotman et al., 2003). Interestingly, the percentage of senescent cells in Pten\textsuperscript{pc−/−} tumors remained constant over time (Figure 1E), in contrast with previous findings in OIS (Kang et al., 2011). These data suggest that, in Pten\textsuperscript{pc−/−} tumors, the adaptive immunity could be impaired, explaining why senescent tumor cells were not removed. To validate this hypothesis, we generated the Pten\textsuperscript{pc−/−}; Rag1\textsuperscript{−/−} mouse model to induce PICS in a genetic background that lacks adaptive immunity (Figure S1H; Mombaerts et al., 1992). Consistent with our hypothesis, Pten\textsuperscript{pc−/−}; Rag1\textsuperscript{−/−} mice developed prostate tumors with size and histology comparable to Pten\textsuperscript{pc−/−} mice (Figure 1F; Kang et al., 2011). More importantly, the percentage of p16 and pHP1\textsuperscript{+} positive cells and SA-β-gal staining between Pten\textsuperscript{pc−/−} and Pten\textsuperscript{pc+/+}; Rag1\textsuperscript{−/−} tumors remained comparable over time (Figures 1E and 1F). Altogether, these data indicate that senescent cells are not removed by the adaptive immunity in Pten\textsuperscript{pc−/−} tumors, in contrast with previous findings in OIS (Kang et al., 2011). Therefore, the lasting senescent cells in these tumors may become a source of mitogenic cytokines that promote tumor progression.

**The Jak2/Stat3 Pathway Is Activated in Pten\textsuperscript{pc−/−} Senescent Tumors**

The SASP of PICS pointed to Stat3 as a putative orchestrator of the SASP of Pten\textsuperscript{pc−/−} tumors such as (C-X-C motif) ligand 1 (CXCL1), CXCL2, interleukin-6 (IL-6), and IL-10 are transcriptionally regulated by Stat3. Therefore, we checked the status of Stat3 phosphorylation in Pten\textsuperscript{pc−/−}...
tumors. Western blot analysis, immunohistochemistry (IHC) staining, and immunofluorescence (IF) confocal imaging revealed that Stat3 was strongly phosphorylated on tyrosine 705 (Y705) in Ptenpc−/− tumors when compared with normal prostates (Figures 2 A–2D, S2A, and S2B). Note that Ptenpc−/+ mice, which develop nonsenescent PIN lesions at 5 months of age (Alimonti et al., 2010; Trotman et al., 2003), stained completely negative for pStat3 (Figures S2A and S2B). Phosphorylation of Stat3 in Ptenpc−/− tumors was also associated with the increased phosphorylation (five times more than in normal prostate) of the nonreceptor Janus kinase 2 (Jak2) (Figure 2A), an upstream activator of Stat3 (Parganas et al., 1998). Interestingly, IF analysis on consecutive sections from Ptenpc−/− tumors revealed that, at the onset of senescence (8–10 weeks), the majority of the pStat3-positive epithelial cells stained negative for pJak2 and positive for the senescence marker p53 protein levels and SA-β-gal-staining positivity, indicating activation of the Jak2/Stat3 pathway in non-cell-autonomous aspects of senescence (Chien et al., 2011). Next, we looked for the presence of senescence in the Ptenpc−/−; Stat3pc−/− tumors and found upregulation of both p53 protein levels and SA-β-gal-staining positivity, indicating that Stat3 was not needed for the execution and maintenance of PICS (Figures 3A and 3B). Next, we checked the status of NF-kB, whose function controls both cell-autonomous and non-cell-autonomous aspects of senescence (Chien et al., 2011), and found that NF-kB was activated to a similar extent in both Ptenpc−/− and Ptenpc−/−; Stat3pc−/− tumors (Figure 3A). Importantly, Stat3 inactivation in both normal and Pten-null prostate epithelium did not affect cell proliferation and apoptosis (Figures S3B and S3C). However, the SASP of Ptenpc−/−; Stat3pc−/− tumors had reduced levels of the immune-suppressive
chemokines (CXCL2, granulocyte colony-stimulating factor, granulocyte macrophage colony-stimulating factor [GM-CSF], macrophage colony-stimulating factor [M-CSF], C5a, IL10, and IL19), whereas retained high levels of potent chemokatransients for B and T cells such as B lymphocyte chemokointactant, monocyte chemokointactant protein-1 (MCP-1), and CXCL10 when compared to the SASP of Ptenpc−/− tumors (Figure 3C; Ansel et al., 2002; Deshmane et al., 2008; Dufour et al., 2002). Taken together, these data demonstrate that inactivation of Stat3 in Pten-null tumors reprograms the SASP of PICS (hereafter referred to as R-SASP) without affecting proliferation, apoptosis, and NF-κB signaling. In line with our findings, Ptenpc−/−; Stat3pc−/− mice developed senescent tumors strongly infiltrated by immune cells. FACS analysis on the immune cell fraction of Ptenpc−/−; Stat3pc−/− mice showed a strong reduction in the percentage of MDSCs (Figure 3D) and increased infiltration of CD8+, NK, and B cells (Figures 3E and 3F). Interestingly, the infiltration of immune cells in the Ptenpc−/−; Stat3pc−/− mouse prostatic epithelium occurred progressively after Pb-Cre activation, reaching a maximum at 15 weeks of age (see Figure S3D). Moreover, in Ptenpc−/−; Stat3pc−/− tumors, both CD8+ and NK cells were cytotoxic, as indicated by the expression of the degranulation marker CD107a (Alter et al., 2004; Ansel et al., 2012; Kang et al., 2011). Notably, whereas at early stage of tumorigenesis, Ptenpc−/−; Stat3pc−/− and Ptenpc−/− tumors had comparable tumor size, at late stages, Ptenpc−/−; Stat3pc−/− tumors were smaller in size (roughly 70%; Figures 3I, 3J, and Figure S4A) and presented a reduced stromal compartment (Figure S4B). Importantly, whereas the total (100%) of Ptenpc−/− mice developed invasive prostate cancer at late stage of tumorigenesis (>15 weeks), only 25% of aged matched Ptenpc−/−; Stat3pc−/− tumors developed invasive prostate tumors (Figures 3J and 3K). All together, our data show that Stat3 inactivation in Pten−/− deficient tumors promotes an immune response switch (from immunosuppressive to active immunosurveillance) by decreasing the levels of specific cytokines in the tumor microenvironment, thus unmasking the immunostimulatory features of the SASP.

**Docetaxel Treatment Enhances Senescence but Does Not Cause Significant Tumor Regression in Pten−Null Prostate Tumors**

We next investigated whether the SASP of PICS could limit the efficacy of treatments that enhance senescence in Pten-null tumors. Docetaxel is the gold standard therapy for recurrent prostate cancer patients that no longer respond to hormonal approaches and is the only US-Food-and-Drug-Administration-approved first-line chemotherapy in these patients (Antonarakis and Armstrong, 2011). Previous evidence showed that docetaxel opposes tumor formation by promoting senescence (Schwarze et al., 2005). We next checked whether docetaxel treatment could be effective in Ptenpc−/− mice by enhancing senescence. Despite the fact that docetaxel treatment enhanced senescence in Pten-null tumors as measured by upregulation of both p16, p21 mRNA levels and immunohistochemistry staining for p16 (Figures SS1A and SS2), it did not trigger a significant reduction in tumor volume (Figure SS1C, bottom). Moreover, we did not detect significant effect of docetaxel treatment on tumor histology (Figure SS1C, top). Of note, the increase in p16 staining correlated with strong activation of pStat3 in tumors (Figure SS2B, bottom) and absence of an antitumor immune response as shown by the low levels of GranzymeB mRNA levels (Figure SS2D). Moreover, in Ptenpc−/− tumors treated with docetaxel, both CD8+ and the NK cells were not cytotoxic, as indicated by lack of the degranulation marker CD107a in those cells (data not shown). In summary, docetaxel treatment increased senescence but had modest activity in Ptenpc−/− tumors. These data are highly relevant considering the frequent loss of PTEN in prostate cancer (Trotman et al., 2003). These findings are also in line with a recent study demonstrating lack of response to docetaxel in patients with prostate cancers with decreased levels of PTEN (Antonarakis et al., 2012).

**Pharmacological Inhibition of the Jak2/Stat3 Pathway Leads to an Effective Antitumor Immune Response in Prostate Tumors Treated with Docetaxel**

We next hypothesized that the modest efficacy of docetaxel in Pten-null tumors was related to the absence of an effective antitumor immune response. Driven by the genetic evidences obtained from Ptenpc−/−; Stat3pc−/− mice, we reasoned that pharmacological inhibition of the Jak2/Stat3 pathway could be an effective strategy to reprogram the SASP and restore an antitumor immune response in docetaxel-treated, Pten-deficient tumors. We tested this hypothesis in a preclinical trial by combining the Jak2 inhibitor NVP-BSK805 (Baffert et al., 2010; Marotta et al., 2011) with docetaxel in a cohort of Ptenpc−/− mice (Figure 4A). In this respect, whereas docetaxel and NVP-BSK805 alone displayed a modest single-agent antitumor response, the combination of docetaxel and NVP-NSK805 led to a profound reduction in tumor size with near complete pathological responses and no evidence of tumor invasion (Figures 4B and 4C). As observed in Ptenpc−/−; Stat3pc−/− tumors, inhibition of the Jak2/Stat3 pathway reprogrammed the SASP in docetaxel-treated mice (Figure 4D), favoring an active immune response, as indicated by the strong infiltration of CD3+ T cells and increased mRNA levels of the cytotoxic marker GranzymeB (Figures 4E and 4F). Of note, the increased intratumor levels of GranzymeB in mice treated with docetaxel+NVP-BSK805 were associated with an increased percentage of apoptotic cells, in agreement with the proapoptotic function of GranzymeB (Trapani and Sutton, 2003; Figure 4G). At 12 weeks of age, both docetaxel- and docetaxel+NVP-BSK805-treated tumors exhibited a strong senescence response, as indicated by SA-β-gal positivity (Figure 4H). However, only in mice treated with docetaxel+NVP-BSK805, senescent cells were surrounded by T cells (Figure 4H). As a consequence, the percentage of senescent cells was strongly reduced in mice treated with NVP-BSK805 alone or in combination with docetaxel (Figure 4I). These data demonstrate that treatments targeting the Jak/Stat3 pathway may be
Figure 3. SASP Reprogramming Promotes an Antitumor Immune Response in Pten\(^{pc-/-}\); Stat3\(^{-/-}\) Mice

(A) Western blot showing the status of p53 and pIKB\(a\) in Pten\(^{pc+/-}\), Pten\(^{pc-/-}\), and Pten\(^{pc-/-}\); Stat3\(^{-/-}\) prostate tumors. DKO, double knockout.

(B) Representative images of SA-\(\beta\)-gal (bottom) and H&E (top) staining of Pten\(^{pc-/-}\) and Pten\(^{pc-/-}\); Stat3\(^{-/-}\) tumors at 15 weeks. Images are magnified \(\times 20\). Inset shows infiltrated immune cells.

(C) Quantification of the cytokine protein profile of purified prostatic epithelial cell isolated from Pten\(^{pc+/-}\), Pten\(^{pc-/-}\), and Pten\(^{pc-/-}\); Stat3\(^{-/-}\) prostates (n = 3).

(legend continued on next page)
successfully used alone, or in combination with prosenescence compounds, to reprogram the SASP and promote an antitumor immune response in Pt-en-deficient tumors.

The Difference between the SASP of PICS and OIS Depends on the Genetic Background of the Senescent Tumor Cells

Previous findings demonstrate that the SASP of NrasG12V-driven senescent tumors trigger senescence surveillance and tumor clearance (Kang et al., 2011). However, the SASP of PICS lacks this capability. We reasoned that the difference in the genetic background of senescent tumor cells could explain this phenomenon. To validate this hypothesis, we used the Kras<sup>LSL-G12D/+;</sup>PbCre prostate conditional mouse model (hereafter referred as to PbKras<sup>G12D</sup>) to compare the effects of the SASP of PICS and OIS in vivo (Tuveson et al., 2004). In agreement with previous findings, PbKras<sup>G12D</sup> mice developed hyperplasia/low-grade PIN in absence of invasive prostate cancer, even at late stage of disease (Figure 5A; Pearson et al., 2009). Notably, PbKras<sup>G12D</sup> prostate lesions from 14-week-old mice were senescent, as demonstrated by increased β-galactosidase staining and p16 mRNA levels (Figures 5A and 5B). Next, we compared the SASP of PICS and OIS by analyzing prostate epithelial cells at the onset of senescence. Surprisingly, the immunosuppressive cytokines upregulated in PICS were only slightly increased in the secretome of OIS. Indeed, PbKras<sup>G12D</sup> tumors were characterized by lower levels of CXCL-2 and IL10 (Figures 5C). Moreover, in stark contrast to PICS, immunohistochemical analysis in PbKras<sup>G12D</sup> senescent tumors showed low level of Stat3 phosphorylation (Figure 5D). Immunophenotyping of PbKras<sup>G12D</sup> tumors revealed that CD11b<sup>+</sup>Gri1<sup>+</sup> cells were almost undetectable when compared with the Pten<sup>pc−/−</sup> tumors (Figure 5E). Moreover, we found an increased percentage of interferon-γ releasing CD8<sup>+</sup>-positive cells in PbKras<sup>G12D</sup> tumors (Figure 5F). Immune-mediated cytotoxic activity, measured by GranzymeB mRNA levels, was also increased in these prostate lesions (Figure 5G). Importantly, in PbKras<sup>G12D</sup> tumor, senescent cells were progressively removed from the tumor, as indicated by the decay of SA-β-gal staining over time (Figure 5H), in agreement with previous findings in a different model of OIS (Kang et al., 2011). In summary, these findings suggest that activation of the Jak2/Stat3 pathway is the key determinant for the different SASPs and senescence-associated immune responses between PICS and OIS. Our data also suggest that compounds that target the Jak2/Stat3 pathway could be more effectively used in PTEN-null tumors rather than in tumors driven by activation of the mitogen-activated protein kinase pathway.

Loss of PTEN Drives Downregulation of PTPN11/SHP2 that Sustains the Activation of the JAK2/STAT3 Pathway

We next sought the mechanism that leads to increased activation of the Jak2/Stat3 pathway in Pt-en-null senescent tumors by focusing on intrinsic regulatory negative systems of this pathway. Protein tyrosine phosphatase (PTP) SHP2 (also known as PTPN11) is one of the major negative regulators of the Jak2/Stat3 pathway. Indeed, hepatocyte-specific deletion of Shp2 in mouse promotes inflammation and tumorigenesis through the activation of Stat3 (Bard-Chapeau et al., 2011). Interestingly, Shp2 mRNA levels were strongly reduced in Pten<sup>pc−/−</sup> tumors when compared to PbKras<sup>G12D</sup> tumors and normal prostates (Figure 6A). Western blot analysis confirmed that the levels of Shp2 were reduced in Pten<sup>pc−/−</sup> tumors at the onset of senescence (Figure 6B). To functionally validate these results in human cancer cell lines, we generated a doxycycline-inducible sh-Pten DU-145 prostate stable cell line (DU-145<sup>sh-Pten</sup>) (Figure 6A). DU-145 cells retain 50% of the endogenous level of PTEN. Strikingly, further downregulation of PTEN was accompanied by the concomitant reduction in both SHP2 protein and mRNA levels and increased phosphorylation of Stat3 at steady state (Figures 6C and 6D). Similar results were also obtained in DU-145 cells when PTEN was downregulated by mean of two different small interfering RNAs (siRNAs) (Figure 6B). Moreover, in a time course experiment, we found that, when DU-145<sup>sh-Pten</sup> cells were starved and stimulated with recombinant IL-6, phosphorylation of Stat3 lasted longer in cells induced with doxycycline (Figure 6D). Finally, rescue experiments showed that, when wild-type (WT) SHP2 was overexpressed in DU-145 cells in presence of siPTEN, the levels of pSTAT3 were reduced (Figure 6C). Consistently, PTPN11/SHP2 downregulation by mean of siRNA in both DU-145 cancer cells and RWPE-1 untransformed cells led to an increase of pSTAT3 protein levels (Figure 6D). These data demonstrate that downregulation of PTEN and SHP2 directly sustained Jak2/STAT3 activation. Note that Shp2 mRNA level remained downregulated in Pten<sup>pc−/−;</sup> Stat3<sup>pc−/−</sup> tumors as well, suggesting that Shp2 is not under the transcriptional control of Stat3 (Figure 6E). Broad bioinformatics analysis conducted on ten different data sets of human prostate cancer (n = 1,086) confirmed the correlation between PTEN and SHP2 (Figures 6E and 6F). Moreover, patients with low levels of both PTEN and SHP2 had a worse prognosis when compared with the other groups (Figure 6F). Lastly, the correlation between PTEN and SHP2 was also validated in a human prostate cancer
tissue microarray (TMA) (Figure 6G). In agreement with our data in mouse models, we also found a strong anticorrelation between decreased PTEN and SHP2 levels (PTEN(low)/SHP2(low)) and increased JAK2 phosphorylation in human prostate tumors (Figure 6G). Of note, this anticorrelation appeared even stronger in prostate cancers with high Gleason score (≥7; Figure 6H). These findings support the emerging view of SHP2 as a potential tumor suppressor also in prostate cancer in line with recent evidence in other tumor types (Bard-Chapeau et al., 2011; Chan and Feng, 2007; Yang et al., 2013). Finally, PTEN and SHP2 correlation was also found in a PANCANCER analysis including 5,703 tumor samples of different histology such as breast, melanoma, lung adenocarcinoma, kidney, and clear cell carcinoma (Figures 7A, S7A, and S7B). As found for prostate cancer patients, low levels of both PTEN and SHP2 were also associated with the worst clinical outcome (Figure 7B).

This finding suggests that the correlation between PTEN and SHP2 levels is a general phenomenon frequently observed in a variety of tumors at different stages of disease.

**DISCUSSION**

The mechanisms that link the SASP to tumorigenesis are poorly understood and remain a subject of intense investigation and debate. On this line, different studies have reported that the SASP can exert pro- as well as antitumorigenic effects (Coppé et al., 2010; Kang et al., 2011; Xue et al., 2007; Rodier and Campisi, 2011; Davalos et al., 2010). However, there has been little investigation into the possibility to reprogram the SASP of a senescent tumor in order to abolish its protumorigenic effects while retaining its immunostimulatory features. In this study, we provide evidence that the SASP of senescent tumors can be both genetically and pharmacologically reprogrammed and that the efficacy of chemotherapy is enhanced in the context of R-SASP. Moreover, our findings demonstrate that the SASP of PICS is orchestrated by both NF-kB and Stat3 activation. Both genetic and pharmacological inactivation of the Jak2/Stat3 pathway does not abolish the SASP of PICS but does drive an overall reprogramming of the senescent secretome retaining a positive NF-kB signature (Chien et al., 2011). On this line, the R-SASP of Pten-null senescent tumors has reduced levels of cytokines, such as CXCL1/CXCL2, GM-CSF, M-CSF, IL10, and IL13, involved in the recruitment and activation of MDSCs but retains increased levels of immunostimulatory chemokine such as MCP-1, previously shown to activate senescence surveillance (Gabrilovich and Nagaraj, 2009; Xue et al., 2007; Zitvogel et al., 2008). Importantly, we provide evidence that R-SASP improves chemotherapy efficacy in Pten-null tumors. Indeed, docetaxel drives a strong senescence response in Pten-null tumors but fails to activate an antitumor immune response and tumor clearance. These findings have immediate implications for the design of clinical trials evaluating the efficacy of docetaxel or novel chemotherapies, whose mechanism of action is based on senescence induction in prostate cancer patients. Our preclinical data predict that single-agent docetaxel will mostly result in disease stabilization, rather than tumor regression, particularly in Pten-null tumors that account for the majority of primary and metastatic prostate cancers and that often retain an intact p53 status (Schliommm et al., 2008). A recent clinical trial demonstrates that Pten-deficient prostate cancer patients are resistant to docetaxel treatment in line with our findings in the mouse model (Antonarakis et al., 2012). In this respect, our data suggest that combined therapy with JAK inhibitors should promote the reprogramming of the SASP, leading to an antitumor immune response in docetaxel-treated patients (Figure S7C, model).

In addition, the direct comparison between two different types of senescent responses in prostate, PICS versus OIS, provides insights on the mechanisms that lead to the establishment of a protumorigenic SASP in senescent tumors. Indeed, in PbKras(G12D)-null senescent tumors (OIS), and in stark contrast to PICS, we did not observe downregulation of SHP2 and activation of Stat3. Absence of Stat3 activation in OIS was associated with a distinct SASP compared to PICS, which was characterized by a lower level of immune-suppressive chemokines and high levels of chemoattractants. This explains the absence of tumor-infiltrating MDSCs, the strong activation of T cells, and the progressive decay in the number of senescence tumor cells in OIS. Because the effects of the SASP have been recently shown to be spatially restricted, it is possible that the levels of the immunosuppressive chemokines secreted by OIS are not sufficient to exert prominent paracrine effects on the tumor microenvironment (Acosta et al., 2013).

Lack of senescence surveillance in PICS, but not OIS, may explain at least in part why Pten-null prostate tumors become invasive at late stage whereas PbKras(G12D) mice develop only benign tumor lesions. All together, these data suggest that

**Figure 4. SASP Reprogramming Enhances Docetaxel Efficacy in Pten(pc−/−) Tumors**

(A) Schedule of treatment used in the preclinical trial with the Jak2 inhibitor NVP-BSK805 and docetaxel in Pten(pc−/−) mice. Starting from 8 weeks of age, mice were treated daily for 4 weeks with a dose of 100 mg/kg of NVP-BSK805 alone or in combination with weekly docetaxel at 10 mg/kg (top). Analysis of tumor volume in the indicated treatment groups (bottom; n = 6–10; *p < 0.05; **p < 0.01).

(B) H&E, pStat3 Y705, and CD3 staining in Pten(pc−/−) tumors treated with NVP-BSK805, docetaxel, and docetaxel+NVP-BSK805. pStat3 staining is used as control to assess inhibition of the Jak2/Stat3 pathway after treatment with NVP-BSK805.

(C) Quantification of PIN-affected glands after the treatments.

(D) Cytokine profile of the reprogrammed SASP (R-SASP) in the indicated treatment groups (n = 5; *p < 0.05; **p < 0.01; mice = 12 weeks of age).

(E) Quantification of the tumor-infiltrating CD3+positive cells shown in (B) (n = 3; **p < 0.01).

(F) GranzymeB mRNA levels in Pten(pc−/−) tumors treated with NVP-BSK805, docetaxel-, and docetaxel+NVP-BSK805-treated tumors (n = 3; *p < 0.05; **p < 0.01; ***p < 0.001).

(G) Quantification of cleaved-caspase 3-positive cells (n = 3; ***p < 0.001).

(H) IF confocal images showing the localization of CD3+-positive cells (red) in close proximity of senescent cells (green).

(i) Representative IF confocal images showing the percentage of pH31γ-positive senescent cells (green) in Pten(pc−/−)-treated mice. Data are represented as mean ± SEM.
**Figure 5. Comparative Analysis of PICS versus OIS in Prostates**

(A) H&E (top) and β-galactosidase staining (bottom) of Pten<sup>pc+/+</sup>, Pten<sup>pc−/−</sup>, and PbKras<sup>(G132D)</sup> prostates at 14 weeks of age.

(B) p16 mRNA levels in Pten<sup>pc+/+</sup>, Pten<sup>pc−/−</sup> (PICS), and Kras<sup>(G12D)</sup> (OIS) prostates.

(C) Different SASP intensity between PICS and OIS (n = 3; *p < 0.05; **p < 0.01).

(D) pSTAT3<sup>Y705</sup> staining (left) and its quantification (right) on paraffin sections from Pten<sup>pc+/+</sup>, Pten<sup>pc−/−</sup> (PICS), and Kras<sup>(G12D)</sup> (OIS) prostates (n = 3).

(E) FACS analysis (and quantification of CD11b<sup>+</sup>GR1<sup>+</sup> cells in Pten<sup>pc+/+</sup>, Pten<sup>pc−/−</sup> [PICS], and Kras<sup>(G12D)</sup> [OIS] prostates). Percentages calculated on CD45<sup>−</sup>-gated cells.

(F) Percentage of interferon-γ-releasing CD8<sup>+</sup> cells (gated on CD45<sup>−</sup> cells) in Pten<sup>pc+/+</sup>, Pten<sup>pc−/−</sup> (PICS), and Kras<sup>(G12D)</sup> (OIS) prostates (n = 3).

(G) Granulocyte mRNA levels in Pten<sup>pc+/+</sup> (PICS), Pten<sup>pc−/−</sup>, Stat3<sup>pc−/−</sup> (PICS), and Kras<sup>(G132D)</sup> (OIS) senescent prostate tumors (n = 3).

(H) Representative images showing the decay of SA-β-galactosidase staining over time (14, 20, and 24 weeks) in Kras<sup>(G132D)</sup> tumors.

Data are represented as mean ± SEM.
Figure 6. Correlation between PTEN and PTPN11/SHP2 Levels in Both Mouse and Human Prostate Cancers

(A) Shp2 mRNA levels in Pten<sup>pc+/+·<sup>PC1<sup>/C0</sup> and in Kras<sup>G12D</sup> (OIS) tumors (n = 3; **p < 0.01).

(B) Western blot analysis showing the reduced Shp2 protein levels in Pten<sup>pc+/+·<sup>PC1<sup>/C0</sup> purified epithelial prostate cells at the onset of senescence (8 weeks Pten<sup>pc+/+·<sup>PC1<sup>/C0</sup> tumors; high-grade PIN and 14 weeks Kras<sup>G12D</sup>; low-grade PIN).

(C) Western blot analysis and quantification of PTEN, SHP2, and STAT3 levels in DU-145 human prostate tumor cells infected with an inducible small hairpin RNA for PTEN.

(D) DU-145 sh-PTEN

E) Prostate cancer Normal prostate

(F) Taylor (high Gleason=89)

(G) Glinsky (high Gleason=62)

(H) Table:

<table>
<thead>
<tr>
<th></th>
<th>PTEN&lt;sup&gt;pc&lt;/sup&gt; vs. SHP2</th>
<th>PTEN&lt;sup&gt;pc&lt;/sup&gt; vs. pJAK2</th>
<th>PTEN&lt;sup&gt;pc&lt;/sup&gt; vs. pJAK2 (Gleason&lt;sup&gt;77&lt;/sup&gt;)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Correlation</td>
<td>Direct</td>
<td>Inverse</td>
<td>Inverse</td>
</tr>
<tr>
<td>Pearson corr. (r)</td>
<td>+0.27</td>
<td>~0.21</td>
<td>~0.34</td>
</tr>
<tr>
<td>p-value</td>
<td>&lt;0.009</td>
<td>&lt;0.009</td>
<td>&lt;0.002</td>
</tr>
<tr>
<td>n&lt;sup&gt;+&lt;/sup&gt; samples</td>
<td>91</td>
<td>91</td>
<td>48</td>
</tr>
</tbody>
</table>

(legend continued on next page)
activation of Jak2/Stat3 pathway is the key determinant underlying the difference between the SASPs of PICS and OIS and demonstrate that the protumorigenic features of the SASP depend on the genetic background of senescent tumor cells.

Our findings establish a direct correlation between the levels of PTEN and SHP2 in both mouse and human tumors. Recent studies have demonstrated that loss of SHP2 activity or deletion of Ptpn11, the gene encoding for SHP2, promote tumorigenesis in different mouse models by sustaining the activation of the JAK/STAT3 pathway (Bard-Chapeau et al., 2011; Zhu et al., 2013; Yang et al., 2013). Our PANCANCER analysis also demonstrated that the correlation between the levels of PTEN and SHP2 exist in different types of human tumors in addition to prostate cancer. Finally, patient stratification based on the levels of PTEN and SHP2 showed that tumors with low levels of both PTEN and SHP2 had the worst prognosis, reinforcing the potential clinical implication of our findings also in a broader scenario beyond the context of senescence tumor lesions.

**EXPERIMENTAL PROCEDURES**

**Mice**

Pten<sup>pc<sup>-/-</sup></sup> mice were generated and genotyped as previously described (Almonti et al., 2010; Chen et al., 2005; Trotman et al., 2003). Stat3<sup>loxP/loxP</sup> mice were generated and provided by Oriental BioService. Rag1<sup>−/−</sup> mice were a kind gift from Prof. Fabio Grassi. Female Pten<sup>pc<sup>-/-</sup></sup>; Stat3<sup>loxP/loxP</sup> and Pten<sup>pc<sup>-/-</sup></sup>; Rag1<sup>−/−</sup> mice were crossed with male P6-Cre4 transgenic mice and genotyped. For Stat3, Stat3<sup>loxP/loxP</sup> primer 1 (5’-CCTGAGACCAAGATTCCAT CTGTGTGAC-3’) and primer 2 (5’-CACACAAGCACTCAAATCTGGTCTCC-3’) were used. For Rag1<sup>−/−</sup> primer 1 (5’-GAGGTTCCGCTACGACTCTG-3’) and primer 2 (5’-CCGAGACTTTTCTCCTG-3’) were used. All mice were maintained under specific pathogen-free conditions in the animal facilities of the Institute for Research in Biomedicine, and experiments were performed according to state guidelines and approved by the local ethics committee.

**Western Blot, Immunohistochemistry, and Immunofluorescence**

Tissue and purified epithelial lysates were prepared with RIPA buffer (1 x PBS, 1% Nonidet P40, 0.5% sodium deoxycholate, 0.1% SDS, and protease inhibitor cocktail [Roche]). The following antibodies were used for western blotting: rabbit polyclonal anti-PTen (9552; Cell Signaling Technology), rabbit monoclonal anti-phospho Stat3 Tyr705 (D3A7; CST), mouse monoclonal Stat3 (124H6; CST), rabbit monoclonal anti-Jak2 (D2E12; CST), rabbit polyclonal anti-phospho-Jak2 (7771; CST), rabbit polyclonal anti-Akt and anti-phospho-serine 473 of Akt (CST), rabbit polyclonal anti-p16 (M156; Santa Cruz Biotechnology), mouse monoclonal anti-p-actin (AC-74; Sigma), rabbit monoclonal anti-SHP2 (C14H6; CST), and rabbit monoclonal anti-SHP-2 (D56F2; CST).

For IHC, tissues were fixed in 10% formalin and embedded in paraffin in accordance with standard procedures. Sections were stained for phospho Stat3 Tyr705(D3A7; CST), Stat3 Tyr705, Pten (51-2400; Invitrogen), KI67(Clone SP6; Lab Vision), anti-CD3 (Dako), and anti-CD45R/B220 (BD Pharmingen). For IF on tissue, paraffin-embedded sections were stained for rabbit monoclonal anti-phospho Stat3 Tyr705(D3A7; CST) and mouse monoclonal anti-α-tubulin (DM1A; CST). Confocal sections were obtained with Leica TCS SP5 confocal microscope.

**Prostatic Epithelial Cell Purification and Cytokine Array**

Pten<sup>pc<sup>−/-</sup></sup>; Stat3<sup>loxP/loxP</sup>, Pten<sup>pc<sup>−/-</sup></sup>; Stat3<sup>loxP/loxP</sup>, and Pten<sup>pc<sup>−/-</sup></sup>; Stat3<sup>loxP/loxP</sup> 9-week-old mice were sacrificed, and whole prostates (n = 3 per group) were isolated and processed to single-cell suspension (Lukacs et al., 2010) for MACS. Single cell suspensions were stained with fluorescein isothiocyanate (FITC)-anti-Cd34 (stroma), FITC-anti-Ter119 (erythrocytes), FITC-anti-Cd31 (endothelial), and FITC-anti-Cd45 (leucocytes) and incubated 20 min on ice. All antibodies (BD Biosciences) were used at 1:300; cells were then loaded into MS column (Miltenyi Biotech) for MACS separation, and unstained epithelial cells were collected in the negative fraction. Purified prostatic epithelial cells were processed as indicated in cytokine array kit (R&D Systems). Developed films were scanned, obtained images were analyzed using ImageJ 1.43u, and background signals were subtracted from the experimental values.

**Autopsy and Histopathology**

Animals were autopsied, and all tissues were examined regardless of their pathological status. Normal and tumor tissue samples were fixed in 10% neutral-buffered formalin (Sigma) overnight. Tissues were processed by

**Figure 7. The Correlation between PTEN and PTPN11/SHP2 Is Frequently Found in Cancer**

(A) Heatmap showing the correlation between PTEN and PTPN11/SHP2 in a PANCACER analysis performed on 25 different tumor types (5,703 samples). (B) Overall survival showing the poor clinical outcome of patients with low levels of both PTEN and PTPN11/SHP2 (red line) when compared with the group of patients with high levels of both PTEN and PTPN11/SHP2 (blue line); the group of patients with low levels of both PTEN and PTPN11/SHP2 are the patients highlighted in the red box of the heatmap of (A).
ethanol dehydration and embedded in paraffin according to standard protocols. Sections (5 μm) were prepared for antibody detection and hematoxylin and eosin (H&E) staining. To evaluate evidence of invasion, sections were cut at 20 μm intervals and H&E stained. Slides were prepared containing three to five of these interval sections.

**Flow Cytometry Analysis of Cell Phenotype**

Samples were acquired on a BD FACSCanto II flow cytometer (BD Biosciences) after fixation with 1% formaldehyde (Sigma-Aldrich). Cells resuspended in PBS containing 1% fetal calf serum (FCS) (Sigma-Aldrich) were stained for 10 min at room temperature with the following anti-mouse monoclonal antibodies: CD45 eFluor 450 (clone 30-F11); CD3e FITC (clone 145-2C11); CD4 allophycocyanin (APC)-eFluor 780 (clone GK1.5); CD8 phycoerythrin (PE) (clone 53-6.7); CD25 PE-Cy7 (clone PC61.5); NK1.1 eFluor 450 (clone PK136); lysesomal-associated membrane protein 1 (CD107a) APC (clone 1D4B); Ly-6G (Gr-1) PE (clone RB6-8C5); CD11b APC (clone M1/70); CD19 FITC (clone 6D5); and CD45R/B220 FITC (clone RA3-8B2). All the antibodies were purchased from ebioScience. GR1’/CD11b’ were sorted from the prostate single-cell suspension using a FACSARia cell sorter (BD Biosciences) after staining with anti-CD45, anti-GR1, and anti-CD11b antibodies for 30 min at 4°C in PBS containing 1% FCS. CD8+ T cells were sorted based on the expression of CD45, CD3, and CD8. Data were analyzed using FlowJo software (TreeStar).

**RNA Expression Analysis**

RNA isolation (QiAGEN) and TaqMan reverse transcriptase reaction (Applied Biosystems) were according to the manufacturer’s instructions. Quantitative PCR reactions (Bio-Rad) for each sample were done in triplicate. Sequences used for PAI-1, IL6, MCP-1, CXCL1, CXCL2, GM-CSF, M-CSF, IL10, ICAM-1, SHP2, PTEN, p14ARF, p16, and eosin (H&E) staining. To evaluate evidence of invasion, sections were cut at 20 μm intervals and H&E stained. Sections (5 μm) were prepared containing three to five of these interval sections.

**Gene Expression Profiling**

Prostate cancer genome-wide gene expression data sets and clinical information were downloaded from Gene Expression Omnibus database or obtained from authors upon request (Glinsky et al., 2004; Setlur et al., 2008; Taylor et al., 2010). Pancancer data set matrix and clinical information was downloaded from University of California, Santa Cruz Cancer Genomics Browser (https://genome-cancer.ucsc.edu). Human cancer cell lines expression data set and sensitivity values to docetaxel treatment (IC50 values) were downloaded from http://www.cancerxgene.org/downloads (Garrett et al., 2012).

**Correlation Analysis**

Correlation between gene-expression-derived values in the principle-component analysis (PCA) and Pancancer data sets was done using Pearson correlation test, which estimates a correlation value “r” and a significance p value (r > 0 < 1, direct correlation; r < 0 > -1, inverse correlation). Correlation was also performed in TMA staining evaluation using the estimated percentage of positively stained cells as determined by a pathologist (M.S.).

**Survival Curves**

Differential survival between patient subgroups was plotted and calculated using Kaplan-Meier curves. Patients were stratified based on PTEN and PTPN11 score values. In brief, scores were rank ordered and divided in seven percentiles (from lowest to highest values). We considered samples having PTEN/PTPN11 low values as those in the first percentile. Such stratification gave significant differences in overall survival within the Pancancer study (log rank test) and in the high Gleason patients within the PCA data sets.

**Statistical Analysis**

Data analysis was performed using a two-tailed unpaired Student’s t test. Values are expressed as mean ± SEM (p < 0.05; **p < 0.01; ***p < 0.001).

**SUPPLEMENTAL INFORMATION**

Supplemental Information includes seven figures and can be found with this article online at http://dx.doi.org/10.1016/j.celrep.2014.08.044.

**AUTHOR CONTRIBUTIONS**


**ACKNOWLEDGMENTS**

We thank all members of the IRB animal core facility for technical assistance and the animal work. We thank Dr. Carole Pissot-Soldermann for developing NVP-BSK805. We thank Dr. Thomas Radimerski for providing NVP-BSK805 and advice on its use. We thank the P.P.P. laboratory for providing the Pten lox/lox mice and paraffin sections of murine invasive prostate cancer and all the members of the A.A. laboratory for the scientific discussions. This work was supported by Swiss National Science Foundation (SNSF) grant Ambizione (PZ00P3_136612/1), European Society for Medical Oncology (ESMO) translational research fellowship, Swiss Bridge Award, PEOPLE-IRG (22484), and European Research Council starting grant (ERCsg 261342) to A.A.; Empires donation to A.R.; and TRAIN Oncology fellowship to A.A. and A.T. All data and materials are available on request.

**SUPPLEMENTAL INFORMATION**

Supplemental Information includes seven figures and can be found with this article online at http://dx.doi.org/10.1016/j.celrep.2014.08.044.
REFERENCES


